Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities
  • Price (EUR)45.00
  • Today's Change-1.37 / -2.95%
  • Shares traded300.00
  • 1 Year change-4.30%
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 14:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eurofins Scientific SE is a Luxembourg-based company engaged in the business support services industry. The Company joins a part of international group of laboratories providing a range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. It operates through a number of subsidiaries, such as VRL Laboratories in the United States, Institut Nehring GmbH in Germany, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain.

  • Revenue in EUR (TTM)6.72bn
  • Net income in EUR576.00m
  • Incorporated2012
  • Employees62.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ERF:PAR since
announced
Transaction
value
Infinity Laboratories IncDeal completed13 Sep 202413 Sep 2024Deal completed-13.88%--
Labormar SASDeal completed08 Jul 202408 Jul 2024Deal completed-5.74%--
Ascend Clinical LLCDeal completed03 Apr 202403 Apr 2024Deal completed-24.70%--
SGS SA-North American Crop Science OperationsAnnounced18 Dec 202318 Dec 2023Announced-22.10%--
Eurofins do Brasil Analises de Alimentos LtdaAnnounced21 Nov 202321 Nov 2023Announced-12.10%--
Data delayed at least 15 minutes, as of Oct 31 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.